Biotechnology Stocks Technical Data -- Anacor Pharma, CytRx, Cerus, CorMedix, and FibroGen

NEW YORK, September 16, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), CytRx Corporation (NASDAQ: CYTR), Cerus Corporation (NASDAQ: CERS), CorMedix Inc. (AMEX: CRMD), and FibroGen Inc. (NASDAQ: FGEN). Free research report on Anacor Pharma can be accessed at https://www.erionline.net/reports?keyword=ANAC On Tuesday, September 15, 2015, the NASDAQ Composite ended at 4,860.52, up 1.14%, the Dow Jones Industrial Average advanced 1.40%, to finish the day at 16,599.85, and the S&P 500 closed at 1,978.09, up 1.28%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.  

On Tuesday, shares in Anacor Pharmaceuticals Inc. recorded a trading volume of 0.39 million shares, lower than their three months average volume of 0.87 million shares. The stock ended the day 0.46% higher at $140.49. Anacor Pharmaceuticals Inc.'s stock has rallied 3.13% in the last one month, 102.90% in the previous three months and 335.63% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 5.47% and 95.89%, respectively. Furthermore, shares of Anacor Pharmaceuticals Inc. have a Relative Strength Index (RSI) of 55.43. Sign up and read the free notes on ANAC at:

https://www.erionline.net/reports?keyword=ANAC

CytRx Corp.'s stock gained 1.76%, to close Tuesday's session at $2.89. The stock recorded a trading volume of 0.35 million shares, below its three months average volume of 0.82 million shares. Over the last one month and since the start of this year, CytRx Corp.'s shares have advanced 22.98% and 5.47%, respectively. However, the stock has plummeted 25.52% since the start of this year. The company is trading 2.37% above its 50-day moving average. Furthermore, CytRx Corp.'s stock has an RSI of 58.55. The complimentary notes on CYTR can be downloaded in PDF format at:

https://www.erionline.net/reports?keyword=CYTR

Cerus Corp.'s stock finished Tuesday's session 1.25% higher at $5.65. A total of 0.44 million shares were traded, which was below its three months average volume of 0.82 million shares. Over the last one month and the previous three months, Cerus Corp.'s shares have gained 18.70% and 4.63%, respectively. However, the stock has lost 9.46% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 9.59% and 12.51%, respectively. Cerus Corp.'s stock has an RSI of 61.65. Register for free on Equity Research Institute and access the latest research on CERS at:

https://www.erionline.net/reports?keyword=CERS

On Tuesday, shares in CorMedix Inc. ended the session 5.98% lower at $2.83. The stock reported a trading volume of 0.65 million shares, below its three months average volume of 0.71 million shares. CorMedix Inc.'s shares have plummeted 7.21% in the last one month and 40.55% in the previous three months. However, the stock has surged 48.17% on YTD basis. The company is trading 11.20% below its 50-day moving average. Moreover, shares of CorMedix Inc. have an RSI of 46.20. The complete research on CRMD is available for free at:

https://www.erionline.net/reports?keyword=CRMD

FibroGen Inc.'s stock edged 0.75% higher, to close the day at $28.24. The stock recorded a trading volume of 0.50 million shares, below its three months average volume of 0.64 million shares. Over the last one month and over the previous three months, FibroGen Inc.'s shares have surged 9.03% and 53.15%, respectively. Furthermore, the stock has gained 3.29% since the start of this year. The company's shares are trading 18.84% and 7.99% above their 50-day and 200-day moving averages, respectively. Additionally, FibroGen Inc. has an RSI of 66.51. Free in-depth research on FGEN is available at:

https://www.erionline.net/reports?keyword=FGEN

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.erionline.net.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) erionline.net.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.erionline.net